Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.

ABSTRACT:

Opinion statement

In the past decade, several endocrine treatment regimens have been developed for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, including tamoxifen, aromatase inhibitors (AI), or a combination of these. The standard duration of adjuvant endocrine treatment has been 5 years for a long time. Nevertheless, the high number of recurrences occurring after 5 years suggested that extended endocrine therapy could further improve outcome, which led to the start of several randomized clinical trials investigating the effects of extended use of endocrine therapy. The extended duration of tamoxifen has been shown to improve disease-free survival and overall survival in the ATLAS and aTTom trials. However, in postmenopausal wo

SUBMITTER: van Hellemond IEG 

PROVIDER: S-EPMC5937869 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature